Form 4: Pulmonx Corp Director Sells 20,000 Shares Under 10b5-1 Trading Plan

A Pulmonx Corp director, Glendon E. French III, sold 20,000 shares of common stock at an average price of $6.63, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Glendon E. French III, a director at Pulmonx Corp, sold 20,000 shares of the company's common stock.
• The sale occurred on November 22, 2024.
• The shares were sold at a weighted average price of $6.63.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on June 10, 2024.
• The sale was part of a series of transactions with prices ranging from $6.50 to $6.79 per share.
• Following the transaction, Mr. French directly owns 1,071,974 shares of Pulmonx Corp.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's fundamentals. It is a neutral event.

Risks

• Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of trading on non-public information, aligning with standard practices in the industry.
• The sale of 20,000 shares is not unusual for a director and is relatively small compared to the total outstanding shares of the company, which is typical for these types of transactions.
• The price range of $6.50 to $6.79 is within the normal trading range for the stock, indicating no unusual price movements associated with this sale.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Pulmonx Corp, insider trading, Form 4, stock sale, Glendon E. French III, Rule 10b5-1, director